Aisling Capital Management LP Viracta Therapeutics, Inc. Transaction History
Aisling Capital Management LP
- $273 Million
- Q4 2024
A detailed history of Aisling Capital Management LP transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Aisling Capital Management LP holds 288,571 shares of VIRX stock, worth $8,657. This represents 0.02% of its overall portfolio holdings.
Number of Shares
288,571
Previous 288,571
-0.0%
Holding current value
$8,657
Previous $66,000
30.3%
% of portfolio
0.02%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
37Shares Held
3.66MCall Options Held
1.8KPut Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$48,7870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA289KShares$8,6750.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$8,5910.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$8,1980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA224KShares$6,7270.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $1.13M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...